Whole study population | Matched population | |||||
---|---|---|---|---|---|---|
FOLFIRINOX (n = 371) | Gemcitabine/nab-paclitaxel (n = 157) | P value | FOLFIRINOX (n = 151) | Gemcitabine/nab-paclitaxel (n = 151) | P value | |
N of cycle during first-line chemotherapy | 9 (4–15) | 5 (3–8) | 9 (4–15) | 5 (3–8) | – | |
Treatment duration of first-line (months) | 5.6 (1.8–9.8) | 4.3 (2.3–7.0) | 0.03 | 5.9 (2.2–10.1) | 4.3 (2.2–6.9) | 0.01 |
Dose reduction during first-line chemotherapy | 172 (46.4) | 57 (36.3)a | 0.03 | 76 (50.3) | 52 (34.4)a | 0.01 |
Interruptionb chemotherapy due to AEs | 25 (6.8) | 46 (29.3) | < 0.001 | 12 (7.9) | 35 (23.1) | < 0.001 |
Cessation treatment | 21 (5.7) | 24 (15.3) | 11 (7.3) | 28 (18.5) | ||
Change regimen | 4 (1.1) | 22 (14.0) | 1 (0.7) | 7 (4.6) | ||
Best responsec | 0.33 | 0.29 | ||||
CR | 4 (1.1) | 0 (0) | 0.18 | 3 (2.0) | 0 (0) | |
PR | 106 (28.9) | 48 (32.4) | 48 (32.0) | 46 (32.4) | ||
SD | 166 (45.2) | 71 (48.0) | 64 (42.7) | 68 (47.9) | ||
PD | 91 (24.8) | 29 (19.6) | 35 (23.3) | 28 (19.7) | ||
Response ratesc | ||||||
ORR | 110 (30.0) | 48 (32.4) | 0.58 | 51 (34.0) | 46 (32.4) | 0.77 |
DCR | 276 (75.2) | 119 (80.4) | 0.21 | 115 (76.7) | 114 (80.3) | 0.45 |
Second-line treatment | 245 (69.2) | 92 (58.6) | 0.02 | 103 (71.5) | 88 (58.3) | 0.02 |
FOLFIRINOX | – | 61 | – | 59 | ||
Nab-paclitaxel | 120 | – | 53 | – | ||
Clinical trial | 33 | 5 | 14 | 4 | ||
Other Gemcitabined | 86 | 0 | 34 | 0 | ||
Other 5-FUe | 6 | 26 | 2 | 25 |